Cassava Sciences again under scrutiny over Alzheimer’s drug research


FDA Headquarters - White Oak Campus


A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer’s candidate simufilam was flagged with a multitude of issues during a September 2022 US FDA inspection.

In that lab, Hoau-Yan Wang


Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button